Dermata Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dermata Therapeutics, Inc. (DRMA) on December 6, 2021. The filing discloses the execution of new employment agreements and amendments for key executive officers, as well as updates to director compensation policies. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The document focuses exclusively on executive compensation terms and director fee adjustments.
Material Changes and Executive Compensation
On December 6, 2021, the Company entered into or amended employment agreements for the following officers:
- Gerald T. Proehl (President and CEO): Base salary of $350,000 annually with a target annual bonus of 50%. Severance for termination without Cause or for Good Reason includes 12 months of base salary. In the event of a Change of Control, severance increases to 18 months of base salary with full equity vesting.
- Kyri Van Hoose (SVP and CFO): Base salary of $270,000 annually with a target annual bonus of 40%. Severance for termination without Cause or for Good Reason includes 9 months of base salary. In the event of a Change of Control, severance increases to 12 months of base salary with full equity vesting.
- Maria Bedoya Toro Munera (SVP, Regulatory Affairs and Quality Assurance): Base salary of $150,000 annually. Terms are otherwise identical to the CFO agreement.
- Christopher Nardo (SVP, Development): An amendment to his August 2021 agreement was executed. Severance for termination without Cause or for Good Reason includes 9 months of base salary. In the event of a Change of Control, severance increases to 12 months of base salary with full equity vesting.
Director Compensation Changes
The Board approved the following changes to the Nominating and Corporate Governance Committee retainers, effective December 6, 2021:
- Chairman: Increased from $7,500 to $8,000 annually.
- Non-Chair Members: Increased from $3,750 to $4,000 annually.
- Equity Election: Directors may now elect to receive 0%, 50%, or 100% of their cash retainer fees in restricted stock units (RSUs).
Outlook, Risks, and Contingencies
The filing does not provide specific guidance, outlook, or risk factors beyond the standard definitions of "Cause," "Good Reason," and "Change of Control" within the employment agreements. The agreements include standard provisions for COBRA health benefit reimbursement upon qualifying termination.
Key Facts for Investor Verification
- Verify the total annual cash compensation obligations for the newly contracted executive team ($770,000 in base salaries).
- Review the specific definitions of "Cause" and "Good Reason" in the attached exhibits to understand termination triggers.
- Assess the potential dilution impact of the new director RSU election policy.
- Confirm the total potential severance liability in a Change of Control scenario, which includes accelerated equity vesting for all four executives.